| 1 |
34149005 | Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan. | 2021 Dec 1 |
2 |
| 2 |
22106207 | Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. | 2012 Feb |
1 |
| 3 |
23157194 | The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs. | 2012 Jun 1 |
1 |
| 4 |
22540071 | Bullous allergic drug eruption with presence of myeloperoxidase and reorganization of the dermal vessels observed by using CD34 and collagen IV antibodies. | 2011 Feb |
1 |
| 5 |
18765684 | Nonenzymatic formation of a novel hydroxylated sulfamethoxazole derivative in human liver microsomes: implications for bioanalysis of sulfamethoxazole metabolites. | 2008 Dec |
1 |
| 6 |
18991696 | Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. | 2008 |
2 |
| 7 |
17442935 | Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. | 2007 May 1 |
1 |
| 8 |
11956677 | Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. | 2002 Apr |
2 |
| 9 |
12019187 | Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. | 2002 Jun |
3 |
| 10 |
10709776 | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. | 2000 Feb |
1 |
| 11 |
10208642 | The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. | 1999 Feb |
9 |
| 12 |
7628308 | N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. | 1995 Mar |
2 |